Nurix Therapeutics (NRIX) Sale and Maturity of Investments (2020 - 2026)
Nurix Therapeutics (NRIX) recorded Sale and Maturity of Investments - Total of $182.42 million in fiscal Q3 2026 (quarter ended Aug 31, 2026), up 16.8% from $156.19 million a year earlier and up 52.6% from the prior quarter.
Nurix Therapeutics (NRIX) Sale and Maturity of Investments (2020 - 2026) Analysis & Trends
On a TTM basis, Nurix Therapeutics' Sale and Maturity of Investments - Total came in at $614.95 million as of Aug 31, 2026, up 3.0% year-over-year; for FY2025 (ended Nov 30, 2025), it came in at $617.54 million, up 34.4% from FY2024.
- Annual Sale and Maturity of Investments - Total has increased for six straight fiscal years, with a five-year compound annual growth rate of 89.3% (FY2020 to FY2025).
- Across earlier fiscal years, Sale and Maturity of Investments - Total came in at $459.51 million in FY2024 (+42.2%), $323.04 million in FY2023 (+15.9%), $278.81 million in FY2022 (+13.4%) and $245.91 million in FY2021 (+869.2%).
- The fiscal Q3 2026 figure is the highest quarterly Sale and Maturity of Investments - Total in data going back to fiscal Q3 2020.
- On a year-over-year basis, Sale and Maturity of Investments - Total rose in six of the last eight quarters, with growth averaging 32.0%.
- Peak year-over-year performance for Sale and Maturity of Investments - Total in the last five years was growth of 424.0% in fiscal Q4 2021, against a decline of 30.2% in fiscal Q1 2023 at the low end.
- Per Business Quant, the preceding three fiscal quarters came in at $119.56 million (Q2 2026), $133.15 million (Q1 2026) and $179.82 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Investments Sold (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,199.50 Bn | 1,168.08 Bn | 19.71 Bn | - |
| 2 | Johnson & Johnson | 635.17 Bn | 555.03 Bn | 17.30 Bn | 308.00 Mn |
| 3 | AbbVie | 504.69 Bn | 477.85 Bn | 12.70 Bn | - |
| 4 | Merck | 358.43 Bn | 312.86 Bn | 12.21 Bn | 1.30 Bn |
| 5 | Novartis Ag | 288.36 Bn | 252.75 Bn | 11.24 Bn | 136.00 Mn |
| 6 | Astrazeneca | 265.78 Bn | 239.54 Bn | 12.86 Bn | - |
| 7 | Amgen | 237.46 Bn | 192.86 Bn | 7.24 Bn | - |
| 8 | Gilead Sciences | 193.65 Bn | 167.76 Bn | 6.22 Bn | 1.03 Bn |
| 9 | Pfizer | 171.05 Bn | 118.00 Bn | 10.94 Bn | 2.12 Bn |
| 10 | Nurix Therapeutics | 2.77 Bn | 141.68 Mn | - | 182.42 Mn |
Historic Data
| Date | Value |
|---|---|
| Aug 31, 2026 | 182.42 Mn |
| May 31, 2026 | 119.56 Mn |
| Feb 28, 2026 | 133.15 Mn |
| Nov 30, 2025 | 179.82 Mn |
| Aug 31, 2025 | 156.19 Mn |
| May 31, 2025 | 142.34 Mn |
| Feb 28, 2025 | 139.20 Mn |
| Nov 30, 2024 | 159.50 Mn |
| Aug 31, 2024 | 110.83 Mn |
| May 31, 2024 | 95.99 Mn |
| Feb 29, 2024 | 93.20 Mn |
| Nov 30, 2023 | 76.61 Mn |
| Aug 31, 2023 | 99.82 Mn |
| May 31, 2023 | 105.62 Mn |
| Feb 28, 2023 | 40.99 Mn |
| Nov 30, 2022 | 84.48 Mn |
| Aug 31, 2022 | 72.77 Mn |
| May 31, 2022 | 62.81 Mn |
| Feb 28, 2022 | 58.75 Mn |
| Nov 30, 2021 | 55.02 Mn |
Nurix Therapeutics Sale and Maturity of Investments API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=sale-and-maturity-of-investments&ticker=NRIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "sale-and-maturity-of-investments", "ticker": "NRIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=sale-and-maturity-of-investments&ticker=NRIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();